Lexaria Bioscience Corp. (Nasdaq: LEXX) announced that dosing began on schedule June 14 for Human Pilot Study #7 (GLP-1-H26-7), a 5-week evaluation of two oral DehydraTECH-semaglutide (DHT-sema) compositions against Novo Nordisk's commercially available Wegovy tablets. The study is fully funded from existing corporate resources.
The company aims to preserve the superior safety and tolerability profiles observed in previous GLP-1 studies, such as Human Study #4 (GLP-1-H24-4), while achieving pharmacokinetic (PK) performance matching or exceeding the Wegovy tablet control. Previous single-dose studies incorporating salcaprozate sodium (SNAC), such as Human Pilot Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2), demonstrated PK performance matching or exceeding Rybelsus control arms with noteworthy safety profiles.
The study investigates three arms comparing SNAC-inclusive DHT-sema compositions in tablet and capsule formats to Wegovy tablets, under fasted pre-dose conditions. The 5-week dosing duration allows achievement of steady-state concentration levels, where semaglutide blood levels reach equilibrium between drug input and elimination.
Key enhancements include the first use of an oral DHT-sema tablet, mimicking physical properties of Rybelsus and Wegovy SNAC-inclusive tablets to follow industry standards and increase likelihood of commercial partnerships. Additionally, both Lexaria's DHT-sema tablet and capsule test articles are formulated with SNAC, evaluated over multiple weeks for the first time. Previous SNAC-inclusive studies were limited to single-dose designs.
The results are expected to be reviewed by the pharmaceutical industry for potential commercial relationships involving Lexaria's DehydraTECH technology. The company holds 66 patents granted worldwide and operates a licensed in-house research laboratory. For more information, visit Lexaria Bioscience.
